A Simplified Approach for the Molecular Classification of Glioblastomas

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Le Mercier, Marie ^a   Hastir, Delfyne ^a   Moles Lopez, Xavier ^b,c   de Nève, Nancy ^a   Maris, Calliope ^a   Trepant, Anne Laure ^a   Rorive, Sandrine ^a,c   Decaestecker, Christine ^b,c   Salmon, Isabelle ^a,c  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c Academie universitaire Wallonie Bruxelles   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN P53; TEMOZOLOMIDE;

AGE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILD; COHORT ANALYSIS; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRESCHOOL CHILD; PROGNOSIS; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84866507582     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045475     Document Type: Article

References (37)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO classification of tumours of the central nervous system; Bosman FT, Jaffe ES, Lakhani SR, Ohgaki H, editors. Lyon: International Agency for Research on Cancer (IARC).
2. Nikiforova MN, Hamilton RL, (2011) Molecular diagnostics of gliomas. Arch Pathol Lab Med 135: 558-568.
3. Ducray F, El Hallani S, Idbaih A, (2009) Diagnostic and prognostic markers in gliomas. Curr Opin Oncol 21: 537-542.
4. Riemenschneider MJ, Jeuken JW, Wesseling P, Reifenberger G, (2010) Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 120: 567-584.
5. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H, (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15: 6002-6007.
6. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, et al. (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27: 4150-4154.
7. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.
8. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003.
9. Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, et al. (2004) Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64: 6503-6510.
10. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, et al. (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173.
11. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, et al. (2009) Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 4: e7752.
12. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
13. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, et al. (2003) Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63: 1602-1607.
14. Huse JT, Phillips HS, Brennan CW (2011) Molecular subclassification of diffuse gliomas: Seeing order in the chaos. Glia.
15. TCGA TCGARN, (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
16. D'Haene N, Maris C, Sandras F, Dehou MF, Remmelink M, et al. (2005) The differential expression of Galectin-1 and Galectin-3 in normal lymphoid tissue and non-Hodgkin's and Hodgkin's lymphomas. Int J Immunopathol Pharmacol 18: 431-443.
17. Rorive S, Lopez XM, Maris C, Trepant AL, Sauvage S, et al. (2010) TIMP-4 and CD63: new prognostic biomarkers in human astrocytomas. Mod Pathol 23: 1418-1428.
18. Decaestecker C, Lopez XM, D'Haene N, Roland I, Guendouz S, et al. (2009) Requirements for the valid quantification of immunostains on tissue microarray materials using image analysis. Proteomics 9: 4478-4494.
19. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97: 1180-1184.
20. Altman DG, McShane LM, Sauerbrei W, Taube SE, (2012) Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 9: e1001216.
21. McShane LM, Altman DG, Sauerbrei W, (2005) Identification of clinically useful cancer prognostic factors: what are we missing? J Natl Cancer Inst 97: 1023-1025.
22. Muris JJ, Meijer CJ, Vos W, van Krieken JH, Jiwa NM, et al. (2006) Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 208: 714-723.
23. Metzger GJ, Dankbar SC, Henriksen J, Rizzardi AE, Rosener NK, et al. (2012) Development of multigene expression signature maps at the protein level from digitized immunohistochemistry slides. PLoS One 7: e33520.
24. Rizzardi AE, Johnson AT, Isaksson Vogel R, Pambuccian SE, Henriksen J, et al. (2012) Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol 7: 42.
25. Kajdacsy-Balla A, Geynisman JM, Macias V, Setty S, Nanaji NM, et al. (2007) Practical aspects of planning, building, and interpreting tissue microarrays: the Cooperative Prostate Cancer Tissue Resource experience. J Mol Histol 38: 113-121.
26. Eguiluz C, Viguera E, Millan L, Perez J, (2006) Multitissue array review: a chronological description of tissue array techniques, applications and procedures. Pathol Res Pract 202: 561-568.
27. Newcomb EW, Madonia WJ, Pisharody S, Lang FF, Koslow M, et al. (1993) A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme. Brain Pathol 3: 229-235.
28. Yoon KS, Lee MC, Kang SS, Kim JH, Jung S, et al. (2001) p53 mutation and epidermal growth factor receptor overexpression in glioblastoma. J Korean Med Sci 16: 481-488.
29. Pollack IF, Hamilton RL, Finkelstein SD, Campbell JW, Martinez AJ, et al. (1997) The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res 57: 304-309.
30. Lopez-Gines C, Gil-Benso R, Ferrer-Luna R, Benito R, Serna E, et al. (2010) New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile. Mod Pathol 23: 856-865.
31. Marquez A, Wu R, Zhao J, Tao J, Shi Z, (2004) Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy. Diagn Mol Pathol 13: 1-8.
32. Hatanpaa KJ, Burma S, Zhao D, Habib AA, (2010) Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia 12: 675-684.
33. Coulibaly B, Nanni I, Quilichini B, Gaudart J, Metellus P, et al. (2010) Epidermal growth factor receptor in glioblastomas: correlation between gene copy number and protein expression. Hum Pathol 41: 815-823.
34. Martinho O, Longatto-Filho A, Lambros MB, Martins A, Pinheiro C, et al. (2009) Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. Br J Cancer 101: 973-982.
35. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, et al. (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64: 6892-6899.
36. Rasheed A, Herndon JE, Stenzel TT, Raetz JG, Kendelhardt J, et al. (2002) Molecular markers of prognosis in astrocytic tumors. Cancer 94: 2688-2697.
37. Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R, et al. (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11: 341-347.